Childhood Cancer Survivorship, Late Cardiotoxicity, and CV Prevention Mini-review: highlights of cardio-oncology
Article Sidebar
Published:
Aug 18, 2016
Main Article Content
Abstract
None
Downloads
Download data is not yet available.
Metrics
Metrics Loading ...
Article Details
How to Cite
1.
Armenian S, Lenihan D. Childhood Cancer Survivorship, Late Cardiotoxicity, and CV Prevention. OncoReview [Internet]. 2016Aug.18 [cited 2024May21];6(3(23):100-2. Available from: https://www.journalsmededu.pl/index.php/OncoReview/article/view/485
Issue
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Armstrong GT, Kawashima T, Leisenring W et al. Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. J Clin Oncol 2014; 32: 1218-1227.
2. Armstrong GT, Oeffinger KC, Chen Y et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol 2013; 31: 3673-3680.
3. Armstrong GT, Plana JC, Zhang N et al. Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol 2012; 30: 2876-2884.
4. Armstrong GT, Joshi VM, Zhu L et al. Increased tricuspid regurgitant jet velocity by Doppler echocardiography in adult survivors of childhood cancer: a report from the St Jude Lifetime Cohort Study. J Clin Oncol 2013; 31: 774-781.
5. Armstrong GT, Chen Y, Yasui Y et al. Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer. N Engl J Med 2016; 374: 833-842.
6. Wang X, Sun CL, Quinones-Lombrana A et al. CELF4 Variant and Anthracycline-Related Cardiomyopathy: A Children’s Oncology Group Genome-Wide Association Study. J Clin Oncol 2016; 34: 863-870.
7. Armenian SH, Xu L, Ky B et al. Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community Based Retrospective Cohort Study. J Clin Oncol 2016; 34: 1122-1130.
8. Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112: e154-e235.
9. Connuck DM, Sleeper LA, Colan SD et al. Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the Pediatric Cardiomyopathy Registry. Am Heart J 2008; 155: 998-1005.
10. Duboc D, Meune C, Pierre B et al. Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years’ follow-up. Am Heart J 2007; 154: 596-602.
11. Rhodes J, Margossian R, Darras BT et al. Safety and efficacy of carvedilol therapy for patients with dilated cardiomyopathy secondary to muscular dystrophy. Pediatr Cardiol 2008; 29: 343-351.
12. Armenian SH, Hudson MM, Mulder RL et al. Recommendations for Cardiomyopathy Surveillance for Survivors of Childhood Cancer: A Report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 2015; 16: e123-e136.
13. Shankar SM, Marina N, Hudson MM et al. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children’s Oncology Group. Pediatrics 2008; 121: e387-e396.
14. Wong FL, Bhatia S, Landier W et al. Cost-effectiveness of the children’s oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure. Ann Intern Med 2014; 160: 672-683.
15. Yeh JM, Nohria A, Diller L. Routine echocardiography screening for asymptomatic left ventricular dysfunction in childhood cancer survivors: a model-based estimation of the clinical and economic effects. Ann Intern Med 2014; 160: 661-671.
16. Lipshultz SE, Rifai N, Dalton VM et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004; 351: 145-153.
17. Lipshultz SE, Adams MJ, Colan SD et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation 2013; 128: 1927-1295.
2. Armstrong GT, Oeffinger KC, Chen Y et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol 2013; 31: 3673-3680.
3. Armstrong GT, Plana JC, Zhang N et al. Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol 2012; 30: 2876-2884.
4. Armstrong GT, Joshi VM, Zhu L et al. Increased tricuspid regurgitant jet velocity by Doppler echocardiography in adult survivors of childhood cancer: a report from the St Jude Lifetime Cohort Study. J Clin Oncol 2013; 31: 774-781.
5. Armstrong GT, Chen Y, Yasui Y et al. Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer. N Engl J Med 2016; 374: 833-842.
6. Wang X, Sun CL, Quinones-Lombrana A et al. CELF4 Variant and Anthracycline-Related Cardiomyopathy: A Children’s Oncology Group Genome-Wide Association Study. J Clin Oncol 2016; 34: 863-870.
7. Armenian SH, Xu L, Ky B et al. Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community Based Retrospective Cohort Study. J Clin Oncol 2016; 34: 1122-1130.
8. Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112: e154-e235.
9. Connuck DM, Sleeper LA, Colan SD et al. Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the Pediatric Cardiomyopathy Registry. Am Heart J 2008; 155: 998-1005.
10. Duboc D, Meune C, Pierre B et al. Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years’ follow-up. Am Heart J 2007; 154: 596-602.
11. Rhodes J, Margossian R, Darras BT et al. Safety and efficacy of carvedilol therapy for patients with dilated cardiomyopathy secondary to muscular dystrophy. Pediatr Cardiol 2008; 29: 343-351.
12. Armenian SH, Hudson MM, Mulder RL et al. Recommendations for Cardiomyopathy Surveillance for Survivors of Childhood Cancer: A Report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 2015; 16: e123-e136.
13. Shankar SM, Marina N, Hudson MM et al. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children’s Oncology Group. Pediatrics 2008; 121: e387-e396.
14. Wong FL, Bhatia S, Landier W et al. Cost-effectiveness of the children’s oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure. Ann Intern Med 2014; 160: 672-683.
15. Yeh JM, Nohria A, Diller L. Routine echocardiography screening for asymptomatic left ventricular dysfunction in childhood cancer survivors: a model-based estimation of the clinical and economic effects. Ann Intern Med 2014; 160: 661-671.
16. Lipshultz SE, Rifai N, Dalton VM et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004; 351: 145-153.
17. Lipshultz SE, Adams MJ, Colan SD et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation 2013; 128: 1927-1295.